Adimab, Novartis Enter Antibody Discovery Pact

Adimab, Inc. has entered into a research collaboration in which it will use its discovery platform to identify fully human antibodies against two targets selected by Novartis. Novartis has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees and is also eligible to receive development milestones and royalties on therapeutic and diagnostic product sales.

“Most pharma companies currently have access to one or more antibody technologies, therefore the success of a new platform requires significant technical and business advantages. The quality of our output, combined with our ability to reduce complex business issues, such as gate-keeping and burdensome royalty obligations, are key aspects to driving broader collaborations with pharma companies,” said Guy van Meter, senior director of business development of Adimab. “Based on our early success, we believe that Adimab’s technology will continue to be in high demand and we are in active discussions with several partners regarding broader unencumbered access and technology transfer.”